FDA 483 - Cordis US Corp - June 29, 2022
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Cordis US Corp in Miami Lakes, FL, revealed significant deficiencies in the firm's design control procedures for their (b)(4) Stent, particularly concerning a new pediatric indication. Observations cited inadequate establishment of procedures for design verification, design input documentation, design validation, and design review. These issues indicate a lack of robust controls to ensure the safety and effectiveness of the device for its intended use.
ID · 2f618886-300c-4bdb-9435-92f09ba6a965